Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552676 | 0.84 | LIPE (1.00) | LIPENPC1RAB9APRMT5KMT2A | |
| SCHEMBL7549063 | 0.84 | LIPE (0.73) | LIPENPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL7552689 | 0.84 | LIPE (0.77) | LIPENPC1RAB9APRMT5WDR77 | |
| SCHEMBL7549708 | 0.81 | LIPE (1.00) | LIPENPC1RAB9APRMT5WDR77 | |
| SCHEMBL7552011 | 0.78 | LIPE (0.70) | LIPEKMT2AMEN1TP53MAPT | |
| SCHEMBL4663481 | 0.77 | LIPE (0.55) | LIPEKMT2AFAAHTP53 | |
| SCHEMBL7550918 | 0.76 | LIPE (0.81) | LIPENPC1RAB9APRMT5WDR77 | |
| SCHEMBL7551658 | 0.76 | LIPE (0.69) | LIPENPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL7549145 | 0.76 | LIPE (1.00) | LIPENPC1RAB9AL3MBTL1 | |
| SCHEMBL7550712 | 0.76 | LIPE (0.80) | LIPENPC1RAB9APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | LIPE 109/4885NPC1 55/4885RAB9A 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.